Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
P/E ratio for Clovis Oncology (CLVS)
P/E ratio on February 22, 2023 (TTM): -0.0430
According to Clovis Oncology's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.042963. At the end of 2012 the company had a P/E ratio of -5.35.
P/E ratio history for Clovis Oncology from 2012 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2012 | -5.35 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | 20.8 | -48,488.38% | 🇺🇸 USA |
 AstraZeneca AZN | 28.4 | -66,192.22% | 🇬🇧 UK |
 Pfizer PFE | 18.2 | -42,498.81% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 17.2 | -40,030.87% | 🇺🇸 USA |
 AbbVie ABBV | 80.9 | -188,426.23% | 🇺🇸 USA |
 Eli Lilly LLY | 63.1 | -146,898.41% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.